D Grabau

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. doi request reprint Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade's experience from a single institution
    D Grabau
    Department of Pathology, Skane University Hospital, Lund, Sweden
    Eur J Surg Oncol 39:601-7. 2013
  2. pmc High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer
    Johan Staaf
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, Lund, Sweden
    Breast Cancer Res 12:R25. 2010
  3. pmc The CD44+/CD24- phenotype is enriched in basal-like breast tumors
    Gabriella Honeth
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, SE 221 85 Lund, Sweden
    Breast Cancer Res 10:R53. 2008
  4. pmc Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
    Quinci Romero
    Department of Oncology, Skane University Hospital, Lund, Sweden
    BMC Cancer 11:341. 2011
  5. doi request reprint Breast cancer patients with micrometastases only: is a basis provided for tailored treatment?
    D Grabau
    Department of Pathology, Pathologic Cytologic Clinic, University Hospital of Lund, 221 85 Lund, Sweden
    Surg Oncol 17:211-7. 2008
  6. doi request reprint Analysis of sentinel node biopsy - a single-institution experience supporting the use of serial sectioning and immunohistochemistry for detection of micrometastases by comparing four different histopathological laboratory protocols
    Dorthe Grabau
    Department of Pathology, University Hospital of Lund, Lund, Sweden
    Histopathology 59:129-38. 2011
  7. doi request reprint The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor
    S Alkner
    Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    Ann Oncol 24:1244-52. 2013
  8. doi request reprint AIB1 is a predictive factor for tamoxifen response in premenopausal women
    S Alkner
    Departments of Oncology, Clinical Sciences, Lund University, Sweden
    Ann Oncol 21:238-44. 2010
  9. doi request reprint Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients
    A M Domanski
    Department of Pathology, Skane University Hospital, Lund, Sweden
    Cytopathology 24:21-5. 2013

Collaborators

  • O Stal
  • P Malmstrom
  • Lisa Rydén
  • S Alkner
  • M Fernö
  • A M Domanski
  • Quinci Romero
  • Niklas Loman
  • Johan Staaf
  • Par Ola Bendahl
  • Markus Ringner
  • Ake Borg
  • Gabriella Honeth
  • Po Bendahl
  • N Monsef
  • H A Domanski
  • Carsten Rose
  • Marie Klintman
  • Christian Ingvar
  • Signe Borgquist
  • K Lovgren
  • Goran Jonsson
  • Rosa B Barkardottir
  • Johan Vallon-Christersson
  • Adalgeir Arason
  • Bjarni A Agnarsson
  • Haukur Gunnarsson
  • P O Bendahl
  • Oskar Th Johannsson
  • Cecilia Hegardt
  • Mårten Fernö
  • Lao H Saal
  • Sofia K Gruvberger-Saal
  • Kristina Lövgren

Detail Information

Publications9

  1. doi request reprint Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade's experience from a single institution
    D Grabau
    Department of Pathology, Skane University Hospital, Lund, Sweden
    Eur J Surg Oncol 39:601-7. 2013
    ..The aim of this retrospective observational study is to determine if the method of detection of early breast cancer is predictive for additional positive nodes in patients with micrometastases in the SNs...
  2. pmc High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer
    Johan Staaf
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, Lund, Sweden
    Breast Cancer Res 12:R25. 2010
    ....
  3. pmc The CD44+/CD24- phenotype is enriched in basal-like breast tumors
    Gabriella Honeth
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, SE 221 85 Lund, Sweden
    Breast Cancer Res 10:R53. 2008
    ..We have explored the prevalence of cells with different CD44/CD24 phenotypes within breast cancer subtypes...
  4. pmc Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
    Quinci Romero
    Department of Oncology, Skane University Hospital, Lund, Sweden
    BMC Cancer 11:341. 2011
    ..Also, a lack of consensus concerning Ki67 assessment may raise problems in the comparison of neo-adjuvant studies. Thus, the secondary aim was to present a novel model for Ki67 assessment...
  5. doi request reprint Breast cancer patients with micrometastases only: is a basis provided for tailored treatment?
    D Grabau
    Department of Pathology, Pathologic Cytologic Clinic, University Hospital of Lund, 221 85 Lund, Sweden
    Surg Oncol 17:211-7. 2008
    ..Tailored systemic therapy is also impossible due to lack of a precisely defined target for a feasible therapy...
  6. doi request reprint Analysis of sentinel node biopsy - a single-institution experience supporting the use of serial sectioning and immunohistochemistry for detection of micrometastases by comparing four different histopathological laboratory protocols
    Dorthe Grabau
    Department of Pathology, University Hospital of Lund, Lund, Sweden
    Histopathology 59:129-38. 2011
    ..2 mm/<200 cells) is important for staging of breast cancer patients. The aim of this study was to systematically compare several laboratory protocols used to detect metastases after initial intraoperative frozen section examination...
  7. doi request reprint The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor
    S Alkner
    Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    Ann Oncol 24:1244-52. 2013
    ..The effect of PAX2 warrants further studies...
  8. doi request reprint AIB1 is a predictive factor for tamoxifen response in premenopausal women
    S Alkner
    Departments of Oncology, Clinical Sciences, Lund University, Sweden
    Ann Oncol 21:238-44. 2010
    ..Materials and methods: A total of 564 premenopausal women were entered into a randomised study independent of ER status. Using a tissue microarray, AIB1 and ER were analysed by immunohistochemistry...
  9. doi request reprint Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients
    A M Domanski
    Department of Pathology, Skane University Hospital, Lund, Sweden
    Cytopathology 24:21-5. 2013
    ..The aim of this study was to compare the ER and PgR immunocytochemical analysis of fine needle aspiration (FNA) samples with the immunohistochemistry (IHC) of surgical specimens and core biopsies from primary breast cancers...